Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

A user shared their 2-month progress using finasteride (1mg) daily, topical minoxidil (5%) daily, and dermarolling twice a week, noting some regrowth and satisfaction with the results. Another user complimented the progress, and the original poster detailed their dermarolling routine.

The user shared their 2 1/2 years of progress treating hair loss with finasteride, minoxidil, and dermarolling, noting a slight improvement from RU58841 and a recent addition of oral minoxidil. They varied their finasteride dosage, used both topical and oral minoxidil, and saw better results with short hair, hoping for further improvement.

Switching generic finasteride manufacturers can reduce side effects while maintaining effectiveness. Different fillers in generics may affect bioavailability and cause varying side effects.

The conversation discusses hair loss and treatments, with users suggesting the original poster's hair has receded despite using a dermaroller and RU58841 for two months. Many recommend starting finasteride and minoxidil for better results.

A 28-year-old is experiencing early signs of balding and is using a routine that includes oral minoxidil, topical dutasteride, microneedling, and ketoconazole shampoo. They are seeking advice on the effectiveness of oral minoxidil with microneedling and the reliability of their product sources.

Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

Microneedling at depths greater than 0.6 mm may damage miniaturized hair follicles, with 0.5 mm showing better results for hair regrowth. Combining microneedling with minoxidil enhances absorption, but caution is advised to avoid damaging follicles.

A user is exploring personalized topical formulations for hair loss from Roots By Genetics Art, specifically interested in the GA-5 Power Restore formulation containing dutasteride, minoxidil, and other ingredients. They seek opinions on the effectiveness and value of these products.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

A user experienced accelerated hairline recession after adding dutasteride to their regimen of topical finasteride and minoxidil, despite reduced hair shedding. They were informed that ELISA testing for DHT levels can be highly inaccurate.

The user "Turbulent_Mix_318" shared their progress pictures after 7 months of using finasteride, dutasteride, and oral minoxidil for hair loss. They did not experience any adverse effects except for increased hair growth in other areas.

Dutasteride 0.5 mg significantly reduces both scalp and hair follicle DHT, with a greater reduction in hair follicle DHT. The discussion questions which reduction is more important for androgenetic alopecia and diffuse thinning.

The user experienced red pimples and a rash from using topical minoxidil, possibly due to propylene glycol. Suggestions included seeing a dermatologist, switching to foam without propylene glycol, using Nizoral, and adjusting application timing.

A 31-year-old has been on finasteride for 8 years and is experiencing less dense hair and itchiness, and is considering adding minoxidil or RU58841 to their regimen. They are also inquiring about the benefits of oral versus topical finasteride.

The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

The conversation is about using RU58841 for hair loss treatment, specifically mixing it with minoxidil without propylene glycol due to an allergy. The user is considering starting with a lower concentration of RU58841 and making smaller batches to maintain efficacy.

The user aims to achieve a hypertrichosis look and has used topical Minoxidil for 20 years, now trying oral Minoxidil in a low dose. They seek alternatives to Minoxidil to avoid side effects.

The user experienced hair regrowth and darker hair using finasteride daily, minoxidil nightly, and occasional dermarolling. They noticed significant progress, especially in hair density, and are considering increasing minoxidil use despite itchiness from wearing a hat.

User experienced hair thickening and slight regrowth using RU58841, Fin, DUT, and Minoxidil. They plan to get a hair transplant in Turkey for further improvement.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

A 21-year-old male experienced negative side effects from oral finasteride and is considering switching to topical finasteride or RU58841 after using oral minoxidil. He seeks advice on a standard hair loss routine, mentioning peptides, RU58841, and dermarolling.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The user is pleased with 4 months of progress using topical minoxidil 5%, finasteride 1mg, and dermarolling 1mm weekly. They are asking if they should expect more results before one year and if they should switch to oral minoxidil.

The user reported modest hair improvement using 1 mg finasteride daily, topical minoxidil twice daily, and weekly microneedling over seven months. Other users discussed their own experiences and encouraged patience, with some suggesting additional treatments like dutasteride and dermarolling.

The conversation is a satirical discussion about hair loss treatments, jokingly suggesting using a Cocker Spaniel as an alternative to actual treatments like finasteride, minoxidil, RU58841, ketoconazole, and dermarolling.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.